Cofactor Genomics Paragon
Feb 08, 2018
Cofactor Genomics has launched Paragon, a cancer type-agnostic solid tumor immune-profiling assay that uses a proprietary database of immune reference signatures to interrogate immune activity associated with disease or therapy response. For example, the assay can differentiate cells such as M1 and M2 macrophages and can report cancer-specific expression signals from genes including PD-1, PD-L1, and CTLA4. The assay requires only two FFPE tissue sections for analysis and can accommodate any solid tumor specimen, with expression databases pre-built for more than 25 different cancer types, Cofactor said.